CTSO big run already after RS and poised for more as market begins to recognize SOC and FDA implications. Inflammation currently has no effective treatment other than hope and prayer.
I had DNDN day of pop from 4 to 15, but left a lot on the table as it climbed for weeks.
Similar with CTIC.
The really good stuff is coming soon. Fresenius partnership is confirmation of big things to come.
Big boys here now. How long will it take to loosen shares bought over 10.00 and shake weak hands with actual profits? Could take a while.
and powerful, that they are able to pretty much scare new buyers away and drop the price at will. Only a sale for serious bucks for any part of MNKD's technology will, IMHO, force capitulation of the shorts. Most shorts are hedged so who knows the magnitude of any eventual squeeze.
A new era of immuno-oncology has arrived...
December 24, 2014 | By Damian Garde
After years of posting impressive clinical results and pushing analyst projections to greater and greater heights, a new class of cancer treatments has finally made its way onto the market, opening up what's expected to become a multibillion-dollar industry.
Leading the way are so-called checkpoint inhibitors, antibodies that unblind the immune system to previously unseen tumors, helping the body's own T cells vanquish cancerous growth. Merck ($MRK) won the first-ever FDA approval for such a treatment with its Keytruda, and Bristol-Myers Squibb ($BMY) followed closely on its heels with Opdivo. Behind them are Roche ($RHHBY) and AstraZeneca ($AZN), at work on similar antibodies, and analysts expect the whole class of therapies to bring in roughly $35 billion a year at its peak. Melanoma is the group's first target, but each contender is carrying out combination studies designed to determine how well PD-1- and PD-L1-blocking therapies can work in tandem with other oncology treatments.
Outside the checkpoint club, Amgen ($AMGN) picked up a lightning-fast approval for its blinatumomab, an immunotherapy targeting blood cancer. The antibody, marketed as Blincyto, is a product of Amgen's bispecific T cell engager (BiTE) system, designed to direct the body's disease-fighting immune cells to attack cancerous growth. It works by connecting CD19, a protein commonly found on cancer cells, to CD3, which is expressed by the immune system's T cells, and Blincyto's approval marks the first nod for any CD19-targeting agent, a class that includes promising immunotherapies from Novartis ($NVS), Juno Therapeutics ($JUNO), Kite Pharma ($KITE) and others.And the agency's pledge to hurry along new treatments that could change the standard of care has encouraged a host of developers.... Less
When we become SOC in one indication, we will become SOC for all very quickly. Filter addresses inflammation which is common thread in all these issues.
Something to watch but their filter works on viruses and byproducts. Patient still dies from cytokine storm which destroys most major organs. Patients typically don't survive without functioning organs, but on the plus side they would have fewer viruses survive which helps with contageon.
At this point I think you are going to have to pay up. When big investors pay 10.40 for a low float issue, I think their expectations are for big moves ahead. Certainly not down from here. 500 - 600 M MC is right for now.
Ticker Company Total return in 2014 (%) Market capitalization ($MIL) Quarterly sales ($MIL)
AVNR Avanir Pharmaceuticals, Inc. Class A 404.5 3,284.5 32.7
OVAS OvaScience, Inc. 383.8 1,075.3 0.0
AGIO Agios Pharmaceuticals, Inc. 367.8 4,103.9 33.9
BLUE Bluebird Bio, Inc. 337.2 2,875.6 6.4
RCPT Receptos, Inc. 322.6 3,792.8 3.5
TGTX TG Therapeutics, Inc. 306.2 696.4 0.0
RNA Prosensa Holding NV 301.5 677.0 0.0
PTX Pernix Therapeutics Holdings PTX +2.76%, Inc. 272.6 359.6 31.5
ACHN Achillion Pharmaceuticals ACHN +8.9%, Inc. 269.1 1,228.0 0.0
FOLD Amicus Therapeutics, Inc. 254.0 774.7 0.3
CTSO CytoSorbents Corporation 218.4 251.6 1.2
PTCT PTC Therapeutics, Inc. 205.1 1,739.6 1.7
ESPR Esperion Therapeutics, Inc. 194.3 823.0 0.0
TTPH Tetraphase Pharmaceuticals, Inc. 193.7 1,217.4 2.3
ISR IsoRay, Inc. 192.0 80.1 1.0
ANIP ANI Pharmaceuticals Inc 180.8 638.9 17.4
CMRX Chimerix, Inc. 166.4 1,468.5 1.2
CBMG Cellular Biomedicine Group, Inc. 153.1 128.4 0.1
HRT Arrhythmia Research Technology, Inc. 142.9 21.2 6.0
NBIX Neurocrine Biosciences, Inc. 139.2 1,698.0 0.0
So we are fourth lowest MC but we have fast ramping sales. Notice the huge MC's with little or no sales.
I think we are finally headed higher. 500-600m MC soon and 2-3B with any indication SOC and/or FDA.
You gotta love it.
till buying volume slows and they all out hammer it lower. Lot of naked shorts that they try to cover end of day. Sec don't care so neither do the hedgies. Leave open naked shorts daily. JMHO.